Michael Chan
5 Papers
Michael Chan is an academic researcher. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 2, co-authored 5 publications.
Chat about Author
Papers
PCDHB15 as a potential tumor suppressor and epigenetic biomarker for breast cancer
Ching-Chung Chiang,Guangfeng Lin,Shuqi Yang,Chi-Wen Tu,Wen-Long Huang,Chun-Feng Wei,Fengwei Wang,Pin-Ju Lin,Wan-Hong Huang,Yu-Ming Chuang,Yu-Ting Lee,Chia-Chou Yeh,Michael Chan,Yu Chen Hsu +13 more
TL;DR: PCDHB15 methylation using cfDNA is a novel minimally invasive epigenetic biomarker for the diagnosis and prognosis of breast cancer and is a potential tumor suppressor in cases of breast cancers which can be epigenetically silenced via promoter methylation.
Abstract 952: Prioritizing mutations associated with smoking as a variable in lung cancer precision medicine with immunotherapies
Margaret R. Smith,Yuezhu Wang,Ralph B. D'Agostino,Yin Lin,Jimmy Ruiz,Thomas Lycan,Umit Topaloglu,Mohammed Abdulhaleem,Michael Chan,Fei Xing +9 more
TL;DR: Smith et al. as mentioned in this paper identified beneficial and harmful mutations in patients that received ICI or chemo-ICI treatment and created an MCS for each smoking statues group and treatment type to assist personalize treatment.
Radt-16. clinical outcomes for high risk who grade ii glioma patients treated with upfront tmz-based chemoradiotherapy
Hosniya Zarabi,R. Wicks,G. Russel,D. Banderage,Roy E. Strowd,Ryan T. Mott,Adrian W. Laxton,Stephen B. Tatter,J. White,Hui-Wen Lo,Waldemar Debinski,Michael Chan,Glenn J. Lesser,Christina K. Cramer +13 more
TL;DR: In this article , the authors analyzed a retrospective dataset of predominantly temozolomide (TMZ)-based CRT in LGG patients who would have been eligible for RTOG 9802 and demonstrated improved survival using chemoradiotherapy (CRT) over radiotherapy alone for WHO Grade II gliomas (LGG) using PCV with RT.
Abstract 5226: Exome-wide association study identifies coding variant in IL17RA associated with survival in cancer patients treated with immunotherapy
TL;DR: Kelleeman et al. as discussed by the authors performed harmonized mutation calling in available normal exome sequencing from 668 metastatic cancer patients treated with ICI and performed exome-wide association studies in European ancestry patients.
NEDD4 degrades TUSC2 to promote glioblastoma progression.
Tadas Rimkus,Austin Arrigo,Dongqin Zhu,Richard L. Carpenter,Sherona Sirkisoon,Daniel Doheny,Angelina T. Regua,Grace L. Wong,Sara G. Manore,Calvin J. Wagner,Hui Kuan Lin,Guangxu Jin,Jimmy Ruiz,Michael Chan,Waldemar Debinski,Hui-Wen Lo +15 more
TL;DR: In this article , NEDD4 E3 ubiquitin ligase polyubiquitinates TUSC2 at residue K71, and the mutant is resistant to proteasomal degradation.